(Reuters) -Pfizer will sell its remaining stake in British consumer healthcare group Haleon, the companies said on Tuesday. Pfizer will sell about 662 million ordinary shares, or 7.3%, of Haleon ...

(Bloomberg) -- Pfizer Inc. raised about £2.55 billion ($3.3 billion) through the sale of its remaining 7.3% stake in Haleon Plc, culminating a years-long separation from the maker of Sensodyne ...

Haleon to invest $54 mln in US R&D centre to ... invest $54 million in its global research and development centre in Richmond, U.S., aiming to boost its pipeline for new product innovations.

March 19 (Reuters) - Drugmaker Pfizer (PFE.N), opens new tab has sold its entire stake in Haleon (HLN.L), opens new tab for about 2.5 billion pounds ($3.24 billion) to institutional investors and ...

With Pfizer’s final stake sale in the bag, the two Big Pharma companies behind Haleon’s genesis have formally parted ways with the standalone consumer health giant. After charting similar ...

Pfizer (NYSE:PFE) has generated £2.5B ($3.24B) after selling its entire stake in Haleon (NYSE:HLN), the consumer healthcare company it established with the British pharmaceutical giant GSK (GSK ...

Pfizer sold its remaining 7.3% stake in Haleon for $3.1 billion, fully exiting its position in the company. Haleon expects 2025 organic revenue growth of 4% to 6%, with stronger performance in the ...

Pfizer reportedly raised about £2.55 billion ($3.3 billion) through the sale of its remaining 7.3% stake in Haleon, ending a years-long separation with the company, per Bloomberg and Yahoo ...

Pfizer sold its entire 7.3% shareholding in London-listed consumer-health company Haleon for a net sum of 2.5 billion pounds ($3.25 billion). Pfizer sold 618 million shares for 385 pence each.

Haleon was formed in 2019 by the merger of the consumer healthcare businesses of British pharmaceutical group GSK and US rival Pfizer. Haleon floated on the London Stock Exchange with a value of ...

LONDON - Haleon plc (LSE/NYSE: HLN), a global leader in consumer health, has announced an agreement with Pfizer Inc. (NYSE:PFE) to buy back approximately £170 million worth of its ordinary shares.